Evidence map›Paper›PMID 39688304›Full record

ArticleMovement disorders clinical practice2025

Utility of Cerebrospinal Fluid Transferrin Receptor per Ferritin Ratio in Progressive Supranuclear Palsy.

Natsuki Akiyama, Masato Kanazawa, Kensaku Kasuga, Masahiro Hatakeyama, Takeshi Ikeuchi, Osamu Onodera

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natsuki AkiyamaDepartment of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
Masato KanazawaDepartment of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0001-6337-8156
Kensaku KasugaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0002-2178-0769
Masahiro HatakeyamaDepartment of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0001-8828-8085
Osamu OnoderaDepartment of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-3354-5472

Funding

Japan Agency for Medical Research and Development JP21dk21444508Japan Society for the Promotion of Science 21K19441
6 · The paper itself

Abstract

backgroundProgressive supranuclear palsy (PSP) is a major atypical parkinsonism. Because diagnosis based on the cardinal clinical features is often difficult, misdiagnosis with Parkinson's disease (PD) and multiple system atrophy (MSA) is common in PSP patients. Iron metabolism genes are reportedly involved in tau-accumulating neuronal cell death and ferroptosis in PSP, which is more severe than PD and MSA. The validity of transferrin receptor (TfR) expression as a biomarker of ferroptosis was also demonstrated.

objectiveWe investigated whether TfR and the TfR to ferritin ratio in the cerebrospinal fluid (CSF) is a diagnostic biomarker of PSP.

methodsThis study included 2 independent retrospective CSF cohorts comprising patients, respectively, from Niigata University and a multicenter memory clinic, consisting of patients with PSP, PD, and MSA. All patients were classified as clinically probable or higher based on the Society of Movement Disorders Criteria. TfR and ferritin levels in the CSF were measured using Luminex assay.

resultsThe levels of TfR in patients with PSP were higher than those in patients with PD and MSA in cohort 1 (PSP: N = 16, PD: N = 13, MSA: N = 20). The TfR to ferritin ratio in patients with PSP was significantly higher than that in patients with MSA. Subsequently, we validated these results in cohort 2 (PSP: N = 23, MSA: N = 6). The TfR to ferritin ratio was significantly higher in patients with PSP than in those with MSA.

conclusionsThe CSF TfR to transferrin ratio was elevated in patients with PSP. These results should be validated in a larger cohort of patients.

Indexed as

FerritinsReceptors, TransferrinSupranuclear Palsy, ProgressiveAgedAged, 80 and overBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedMultiple System AtrophyParkinson DiseaseRetrospective StudiesBiomarkersFerritinsReceptors, Transferrinferritinferroptosisprogressive supranuclear palsy (PSP)transferrin receptor

Identifiers

PMID39688304
PMCPMC11998682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.